Study of Multiple Oral Doses of Odanacatib (MK0822) in Healthy Adults (0822-002)

A Double-Blind, Randomized, Placebo-Controlled, Multi-Panel, Multiple Oral Dose Study, to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0822 in Healthy Male and Postmenopausal Female Subjects

This study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of once-daily multiple-dose administration of odanacatib (MK0822).

Inclusion Criteria:

• Subject is a male between the ages of 18 and 45 or a female less than or equal to 70 years of age
• Females must be past menopause
• Subject is a nonsmoker
• Subject is willing to avoid excessive alcohol consumption during the study and is willing to avoid alcohol entirely for 24 hours prior to drug administration and during PK sampling
• Subject is willing to refrain from consuming grapefruit or grapefruit juice

Exclusion Criteria:

• Subject has a history of multiple/severe allergies to drugs or food
• Subject has donated blood within 4 weeks of starting the study
• Subject has a history of metabolic bone disease, urolithiasis, or bisphosphonate treatment
• Subject has any infections or any condition leading to immune problems, including HIV
• Subject regularly uses illegal drugs
• Subject consumes more than 3 alcoholic beverages per day
• Subject drinks 4 or more caffeinated beverages per day
• Subject uses any prescription or nonprescription medications